SALT LAKE CITY, Sept. 26, 2017 /PRNewswire/ — DiscGenics, Inc., a clinical stage regenerative medicine company focused on developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced it has closed a $14 million Series B financing. The round brings DiscGenics’ total funding to $21.7 million, and […]